Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Accenture
Harvard Business School
Medtronic
Healthtrust
AstraZeneca
Deloitte
Farmers Insurance

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,269,040

« Back to Dashboard

Which drugs does patent 8,269,040 protect, and when does it expire?

Patent 8,269,040 protects PRISTIQ and is included in one NDA.

This patent has twenty patent family members in sixteen countries.
Summary for Patent: 8,269,040
Title:Derivatives of venlafaxine and methods of preparing and using the same
Abstract: Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
Inventor(s): Jerussi; Thomas P. (Framingham, MA), Senanayake; Chrisantha H. (Shrewsbury, MA), Bhongle; Nandkumar N. (Shrewsbury, MA)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:10/720,134
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,269,040

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Wyeth Pharms Inc PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,269,040

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 514612 ➤ Subscribe
Poland 350924 ➤ Subscribe
Portugal 1466889 ➤ Subscribe
Norway 20100496 ➤ Subscribe
Norway 20014816 ➤ Subscribe
Japan 2003521470 ➤ Subscribe
Hungary 0200898 ➤ Subscribe
Spain 2305606 ➤ Subscribe
European Patent Office 2133325 ➤ Subscribe
European Patent Office 1905757 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
US Department of Justice
Medtronic
Mallinckrodt
Teva
Chinese Patent Office
Boehringer Ingelheim
Deloitte
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot